Dendritic cell-based tumor-specific immunotherapy against malignant brain tumor - Phase I clinical trial

Dendritic cell-based tumor-specific immunotherapy against malignant brain tumor - Phase I clinical trial - Immunotherapy against malignant brain tumor

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000914

Enrollment

Registered

2009-12-01

Start date

2007-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant brain tumor (malignant glioma)

Interventions

Administration of multiple peptides-treated activated dendritic cell vaccines to malignant glioma patients in a dose-escalation manner

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histological diagnosis of malignant glioma 2. Poor response to standard treatment (SD or PD) 3. 20 <= Age <80 4. Performance status; 0-2 5. Measurable lesions in imaging diagnosis 6. HLA genotyping ; HLA-A2 or A24 7. No severe organ dysfunction 8. No severe hematostatic dysfunction 9. Informed consents obtained from patients 10. Survival for more than 6 months expected 11. More than 4 weeks interval after last treatment against cancer

Exclusion criteria

Exclusion criteria: 1. Within 28 days after the last treatment against cancer 2. Severe systemic infection, hematostatic dysfunction, and organ disorder 3. Steroid treatment, except used for cerebral decompression 4. Hypersensitivity to DC vaccine 5. Severe immunological disorders (autoimmune disease, immunosuppression) 6. Multiple cancers 7. Anaphylaxis to synthetic peptides

Design outcomes

Primary

Measure	Time frame
Safety of immunotherapy	—

Secondary

Measure	Time frame
Antitumor effect, Immunological effect	—

Countries

Japan

Contacts

Public ContactYasuto Akiyama, M.D.

Shizuoka Cancer Center Research Institute Immunotherapy Division

y.akiyama@scchr.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026